Korlym controls hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have diabetes mellitus type 2 or glucose intolerance and have failed surgery or are not candidates for surgery.
Corcept CEO Joseph Belanoff said they plan to make Korlym available to patients by May 1 through a distribution system designed to support both patients and prescribers.
"We appreciate the FDA’s diligent attention to our NDA and its grant of approval on the PDUFA date," Belanoff added.